- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
[作者:Godin-Ethier, J; Hanafi, LA; Piccirillo, CA; Lapointe, R,期刊:Clinical Cancer Research, 页码:6985-6991 , 文章类型: Review,,卷期:2011年17-22]
- Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme with immune-regulating activities in many contexts, such as fetal protection, allograft protection, and cancer progression. Clinical trials are curren...
- Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
[作者:Sippel, TR; White, J; Nag, K; Tsvankin, V; Klaassen, M; Kleinschmidt-DeMasters, BK; Waziri, A,期刊:Clinical Cancer Research, 页码:6992-7002 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: The source of glioblastoma (GBM)-associated immunosuppression remains multifactorial. We sought to clarify and therapeutically target myeloid cell-derived peripheral immunosuppression in patients with GBM.Experi...
- Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB-NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome
[作者:Mitani, Y; Rao, PH; Futreal, PA; Roberts, DB; Stephens, PJ; Zhao, YJ; Zhang, L; Mitani, M; Weber, RS; Lippman, SM; Caulin, C; El-Naggar, AK,期刊:Clinical Cancer Research, 页码:7003-7014 , 文章类型: Article,,卷期:2011年17-22]
- Objective: To investigate the molecular genetic heterogeneity associated with the t(6:9) in adenoid cystic carcinoma (ACC) and correlate the findings with patient clinical outcome.Experimental Design: Multimolecular and ...
- Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma
[作者:Chang, DZ; Ma, Y; Ji, BA; Wang, HM; Deng, DF; Liu, Y; Abbruzzese, JL; Liu, YJ; Logsdon, CD; Hwu, P,期刊:Clinical Cancer Research, 页码:7015-7023 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death. No effective therapy is currently available for PDAC because of the lack of understanding of the mechanisms leading to its gr...
- Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis
[作者:Bhattacharya, A; Roy, R; Snijders, AM; Hamilton, G; Paquette, J; Tokuyasu, T; Bengtsson, H; Jordan, RCK; Olshen, AB; Pinkel, D; Schmidt, BL; Albertson, DG,期刊:Clinical Cancer Research, 页码:7024-7034 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: Problems in management of oral cancers or precancers include identification of patients at risk for metastasis, tumor recurrence, and second primary tumors or risk for progression of precancers (dysplasia) to ca...
- Serum Galectin-2,-4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
[作者:Barrow, H; Guo, XL; Wandall, HH; Pedersen, JW; Fu, B; Zhao, QC; Chen, C; Rhodes, JM; Yu, LG,期刊:Clinical Cancer Research, 页码:7035-7046 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: Adhesion of disseminating tumor cells to the blood vascular endothelium is a pivotal step in metastasis. Previous investigations have shown that galectin-3 concentrations are increased in the bloodstream of pati...
- Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
[作者:Li, YH; Wang, LX; Pang, PY; Cui, ZH; Aung, S; Haley, D; Fox, BA; Urba, WJ; Hu, HM,期刊:Clinical Cancer Research, 页码:7047-7057 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: We previously reported that autophagy in tumor cells plays a critical role in cross-presentation of tumor antigens and that autophagosomes are efficient antigen carriers for cross-priming of tumor-reactive CD8(+...
- Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
[作者:Cruz, CR; Gerdemann, U; Leen, AM; Shafer, JA; Ku, S; Tzou, B; Horton, TM; Sheehan, A; Copeland, A; Younes, A; Rooney, CM; Heslop, HE; Bollard, CM,期刊:Clinical Cancer Research, 页码:7058-7066 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: Patients with Hodgkin lymphoma (HL) relapsing after hematopoietic stem cell transplant have limited options for long-term cure. Wehave shown that infused cytotoxic T cells (CTL) targeting Epstein Barr virus (EBV...
- Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells
[作者:Hoglund, A; Nilsson, LM; Muralidharan, SV; Hasvold, LA; Merta, P; Rudelius, M; Nikolova, V; Keller, U; Nilsson, JA,期刊:Clinical Cancer Research, 页码:7067-7079 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: The transcription factor c-Myc (or "Myc") is a master regulator of pathways driving cell growth and proliferation. MYC is deregulated in many human cancers, making its downstream target genes attractive candidat...
- Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies
[作者:Lee, HJ; Wall, BA; Wangari-Talbot, J; Shin, SS; Rosenberg, S; Chan, JLK; Namkoong, J; Goydos, JS; Chen, S,期刊:Clinical Cancer Research, 页码:7080-7092 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: Melanoma is a heterogeneous disease where monotherapies are likely to fail due to variations in genomic signatures. B-RAF inhibitors have been clinically inadequate but response might be augmented with combinati...
- Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma
[作者:Fang, H; Harned, TM; Kalous, O; Maldonado, V; DeClerck, YA; Reynolds, CP,期刊:Clinical Cancer Research, 页码:7093-7104 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: Fenretinide (4-HPR) is a cytotoxic retinoid with minimal systemic toxicity that has shown clinical activity against recurrent high-risk neuroblastoma. To identify possible synergistic drug combinations for futur...
- Reduced miR-128 in Breast Tumor-Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5
[作者:Zhu, YH; Yu, FY; Jiao, Y; Feng, J; Tang, W; Yao, HR; Gong, C; Chen, JN; Su, FX; Zhang, Y; Song, EW,期刊:Clinical Cancer Research, 页码:7105-7115 , 文章类型: Article,,卷期:2011年17-22]
- Purpose: Tumor-initiating cells are resistant to chemotherapy, but how microRNAs play a role in regulating drug resistance of breast tumor-initiating cells (BT-IC) needs to be clarified.Experimental Design: Lentivirus-me...
|